THE AMENDMENT

In the Claims

1. (Currently Amended) A parvovirus vector ~~having~~ comprising a parvovirus DNA ~~excisable from the vector DNA in a parvovirus-permissive cell, wherein the parvovirus DNA has~~ having a left terminus which comprises a parvovirus minimal origin of replication CTWWTCA, wherein W is any nucleotide, and the parvovirus DNA is excisable from the parvovirus vector in a parvovirus-permissive cell.

2. (Previously Amended) The parvovirus vector according to claim 1, wherein the left terminus of the parvovirus DNA comprises internal replication sequences.

3. (Currently Amended) The parvovirus vector according to claim 1 or 2, wherein the ~~parvovirus minimal origin of replication comprises~~ CTWWTCA sequence is a consensus sequence of an MVM NS1 nicking site.

4. (Previously Amended) The parvovirus vector according to claim 1 or 2, wherein the parvovirus DNA originates from a mammalian parvovirus.

5. (Previously Amended) The parvovirus vector according to claim 1 or 2, wherein the parvovirus DNA is a rodent parvovirus.

6. (Previously Amended) The parvovirus vector according to claim 5, wherein the rodent parvovirus is MVM or H-1.

7. (Previously Amended) The parvovirus vector according to claim 1 or 2, wherein the parvovirus DNA comprises a combination of DNA sequences of various parvoviruses.

8. (Previously Amended) The parvovirus vector according to claim 7, wherein the parvovirus DNA originates from H-1 and the left terminus comprises a minimal parvovirus origin of replication of MVM.

9. (Previously Amended) The parvovirus vector according to claim 1 or 2, wherein the parvovirus DNA region coding for capsid proteins is partially or fully replaced by an exogeneous DNA.

10. (Previously Amended) The parvovirus vector according to claim 9, wherein the exogeneous DNA codes for a polypeptide usable in a treatment.

11. (Previously Amended) The parvovirus vector according to claim 10, wherein the polypeptide is a cytokine or a toxin.

12. (Previously Amended) The parvovirus vector according to claim 11, wherein the cytokine is a chemotactic polypeptide.

13. (Previously Amended) The parvovirus vector according to claim 12, wherein the chemotactic polypeptide is MCP-1.

14. (Previously Amended) The parvovirus vector according claim 1 or 2, wherein the parvovirus vector is present as a parvoviral particle.

15. (Previously Amended) A system comprising the parvovirus vector according to claim 9 and a cell expressing the capsid proteins of parvovirus.

16. (Previously Amended) The system according to claim 15, wherein the expression of the capsid proteins is controlled by a helper plasmid comprising an SV40 origin of replication and the cell expresses an SV40 large T antigen.

17. (Previously Amended) The system according to claim 15, wherein the DNA coding for the capsid proteins is under the control of the parvovirus promoter P38.

18. (Previously Amended) A method of producing the parvoviral particle according to claim 14, comprising the steps of:
transfecting a parvovirus-permissive cell with the parvovirus vector according to claim 9,
expressing the capsid proteins of a parvovirus in the cell, and
isolating the parvoviral particle.

19. (Currently Amended) ~~Use of~~ A method for providing gene therapy, comprising the steps of transfecting parvovirus-permissive cells with the parvovirus vector according claim 9 ~~for gene therapy~~, and expressing the exogeneous DNA in the cells.

20. (Currently Amended) ~~Use~~ The method according to claim 19, wherein the gene therapy is carried out in the case of tumor diseases.

21. Canceled.